Male Infertility Global Market Opportunities and Strategies to 2034

This report describes and explains the male infertility market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global male infertility market reached a value of nearly $4.1 billion in 2024, having grown at a compound annual growth rate (CAGR) of 4.19% since 2019. The market is expected to grow from $4.1 billion in 2024 to $5.42 billion in 2029 at a rate of 5.76%. The market is then expected to grow at a CAGR of 5.55% from 2029 and reach $7.1 billion in 2034.

Growth in the historic period resulted from the impact of delayed parenthood, rise in medical tourism, rise in environmental and occupational hazards and rising investments in R&D and fertility biotech. Factors that negatively affected growth in the historic period were high cost of treatment and limited insurance coverage.

Going forward, the growth in fertility clinics and reproductive health services, government initiatives, increasing stress levels and increasing incidence of lifestyle disorders will drive the growth. Factor that could hinder the growth of the male infertility market in the future include regulatory and ethical issues, social stigma and lack of awareness and impact of trade war and tariff.

North America was the largest region in the male infertility market, accounting for 29.27% or $1.2 billion of the total in 2024. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the male infertility market will be Asia Pacific and South America where growth will be at CAGRs of 6.55% and 6.18% respectively. These will be followed by North America and Eastern Europe where the markets are expected to grow at CAGRs of 5.74% and 5.69% respectively.

The global male infertility markets is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 25.54% of the total market in 2024. The Bayer AG was the largest competitor with 5.22% share of the market, followed by Merck KGaA / Merck Serono with 5.05%, Zydus Lifesciences with 3.70%, Intas Pharmaceuticals Ltd with 3.34%, CooperSurgical Inc. with 2.24%, Vitrolife Group (Vitrolife AB) with 2.09%, CinnaGen Co. with 1.59%, Kindbody Inc. with 0.98%, Aytu BioScience Inc. with 0.90% and Fortis Healthcare Ltd. with 0.42%.

The male infertility market is segmented by treatment type into medication, surgery and assisted reproductive technology (ART). The assisted reproductive technology (ART) market was the largest segment of the male infertility market segmented by treatment type, accounting for 46.45% or $1.9 billion of the total in 2024. Going forward, the assisted reproductive technology (ART)segment is expected to be the fastest growing segment in the male infertility market segmented by treatment type, at a CAGR of 6.42% during 2024-2029.

The male infertility market is segmented by test type into sperm agglutination, deoxyribonucleic acid (DNA) fragmentation technique, oxidative stress analysis, computer assisted semen analysis, sperm penetration assay and other test types. The deoxyribonucleic acid (DNA) fragmentation technique market was the largest segment of the male infertility market segmented by test type, accounting for 22.84% or $937.07 million of the total in 2024. Going forward, the oxidative stress analysis segment is expected to be the fastest growing segment in the male infertility market segmented by test type, at a CAGR of 8.42% during 2024-2029.

The male infertility market is segmented by end-user into hospitals and clinics, fertility centers, research institutes and other end-users. The fertility centers market was the largest segment of the male infertility market segmented by end-user, accounting for 44.17% or $1.81 billion of the total in 2024. Going forward, the fertility centers segment is expected to be the fastest growing segment in the male infertility market segmented by end-user, at a CAGR of 6.27% during 2024-2029.

The top opportunities in the male infertility markets segmented by treatment type will arise in the assisted reproductive technology segment, which will gain $695.16 million of global annual sales by 2029. The top opportunities in the male infertility markets segmented by test type will arise in the deoxyribonucleic acid fragmentation technique segment, which will gain $409.37 million of global annual sales by 2029. The top opportunities in the male infertility markets segmented by end-user will arise in the fertility centers segment, which will gain $643.79 million of global annual sales by 2029. The male infertility market size will gain the most in the USA at $300.86 million.

Market-trend-based strategies for the male infertility market include focus on strategic investment, to accelerate the development of novel diagnostic tools and treatments, expand their technological capabilities, and capture a larger share of the growing fertility care market, focus on developing at-home fertility test for gaining competitive advantage, focus on developing at-home sperm testing kit, to offer men a convenient, private, and accessible way to assess their fertility and focus on strategic partnership, to expand access to fertility care, integrate complementary technologies and expertise.

Player-adopted strategies in the male infertility market include focus on developing business expertise through strategic partnerships and focus on enhancing business operations through strategic acquisitions.

To take advantage of the opportunities, the analyst recommends the male infertility companies to focus on strategic investment to advance diagnostic and therapeutic innovation, focus on at-home fertility testing to expand access and drive differentiation, focus on assisted reproductive technology to capture high-growth market share, focus on oxidative stress analysis to maximize growth potential, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use B2B promotions, focus on strategic partnerships to broaden access and support early male fertility evaluation and focus on fertility centers to accelerate market penetration.

This product will be delivered within 3-5 business days.